Phenibut and Trazodone Interaction: Monitor | Peptide Database

Silenor (doxepin 3 mg and 6 mg) is FDA-approved for the treatment of insomnia characterized by difficulty with sleep maintenance. Clinical trials demonstrated that ultra-low dose doxepin significantly improved sleep maintenance (wake after sleep onset) and total sleep time without next-morning residual effects at the 3 mg dose, and with minimal residual effects at 6 mg. At higher doses (75-300 mg), doxepin is FDA-approved for the treatment of depression and anxiety associated with depression. However, this use is largely historical, as newer antidepressants with more favorable side effect profiles have supplanted TCAs for most patients. The antidepressant dosing range is entirely separate from the ultra-low dose sleep application. Clinical data supports the efficacy and safety of ultra-low dose doxepin for long-term insomnia management. Unlike many hypnotics, doxepin at 3-6 mg maintains its efficacy over months of continuous use without dose escalation, making it suitable for chronic insomnia in patients who need a sustainable, long-term solution. Ultra-low dose doxepin is one of the few sleep medications with specific safety and efficacy data in elderly patients. The 3 mg dose is recommended for older adults and has been shown to improve sleep maintenance without the falls, cognitive impairment, and next-day sedation risks associated with benzodiazepines and Z-drugs in this population.

Nandrolone (Deca-Durabolin and NPP) elevates prolactin through progestogenic activity. Cabergoline is considered the gold standard for preventing and treating prolactin-related side effects during nandrolone cycles, including sexual dysfunction and progesterone-mediated gynecomastia. Trenbolone is a potent progestin that can significantly elevate prolactin in some users. Cabergoline controls prolactin-driven side effects such as lactation, nipple sensitivity, erectile dysfunction, and anorgasmia that may occur during trenbolone cycles. Elevated prolactin from 19-nor compounds commonly causes decreased libido, erectile dysfunction, and difficulty reaching orgasm (often called 'deca dick'). Cabergoline restores normal sexual function by normalizing prolactin levels. FDA-approved for the treatment of hyperprolactinemic disorders of various etiologies, including idiopathic hyperprolactinemia and prolactin-secreting pituitary adenomas (micro- and macroadenomas). Normalizes prolactin in over 85% of patients. First-line medical therapy for prolactin-secreting pituitary tumors. Cabergoline achieves significant tumor size reduction in the majority of patients, often avoiding the need for surgical intervention.